Search

Your search keyword '"Meropol, Neal J."' showing total 1,006 results
Start Over Author "Meropol, Neal J."
1,006 results on '"Meropol, Neal J."'

1. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Author

Mezzanotte-Sharpe, Jessica, ONeill, Anne, Mayer, Ingrid A., Arteaga, Carlos L., Yang, Ximing J., Wagner, Lynne I., Cella, David, Meropol, Neal J., Alpaugh, R. Katherine, Saphner, Thomas J., Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J., Abramson, Vandana G., Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A., Lin, Nancy U., Jahanzeb, Mohammad, Wolff, Antonio C., Sledge, George W., and Reid, Sonya A.

Published
2024
Full Text
View/download PDF

2. A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Author

Mezzanotte-Sharpe, Jessica, primary, ONeill, Anne, additional, Mayer, Ingrid A., additional, Arteaga, Carlos L., additional, Yang, Ximing J, additional, Wagner, Lynne I., additional, Cella, David, additional, Meropol, Neal J., additional, Alpaugh, R. Katherine, additional, Saphner, Thomas J., additional, Swaney, Robert E., additional, Hoelzer, Karen L, additional, Gradishar, William J., additional, Abramson, Vandana G., additional, Sundaram, P. Kothai, additional, Jilani, Shamim Z., additional, Perez, Edith A., additional, Lin, Nancy U., additional, Jahanzeb, Mohammad, additional, Wolff, Antonio C., additional, Sledge, George W., additional, and Reid, Sonya A., additional

Published
2024
Full Text
View/download PDF

4. Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics.

Author

Altomare, Ivy, Wang, Xiaoliang, Kaur, Maneet, Guadamuz, Jenny S, Falk, Sam, Xiao, Forrest, Meropol, Neal J, and Zhao, Yihua

Subjects
MEDICAL research, REGRESSION analysis, AGE groups, DATABASES, CLINICAL trials
Abstract

Background Expanding access to clinical trials in community settings is a potential approach to addressing disparities in accrual of historically underrepresented populations. However, little is known about the characteristics of practices that do not participate in research. We investigated differences in patient and practice characteristics of US community oncology practices with high vs low engagement in clinical research. Methods We included patients from a real-world, nationwide electronic health record–derived, de-identified database who received active treatment for cancer at community oncology practices between November 1, 2017, and October 31, 2022. We assessed patient and practice characteristics and their associations with high vs low research engagement using descriptive analyses and logistic regression models. Results Of the 178 practices, 70 (39.3%) events had high research engagement, treated 57.8% of the overall 568 540 patient cohort, and enrolled 3.25% of their patients on cancer treatment trials during the 5-year observation period (vs 0.27% enrollment among low engagement practices). Practices with low vs high research engagement treated higher proportions of the following patient groups: ages 75 years and older (24.2% vs 21.8%), non-Latinx Black (12.6% vs 10.3%) or Latinx (11.6% vs 6.1%), were within the lowest socioeconomic status quintile (21.9% vs16.5%), and were uninsured or had no documented insurance (22.2% vs 13.6%). Conclusions Patient groups historically underrepresented in oncology clinical trials are more likely to be treated at community practices with limited or no access to trials. These results suggest that investments to expand the clinical research footprint among practices with low research engagement could help address persistent inequities in trial representation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Future cancer research priorities in the USA: a Lancet Oncology Commission

Author

Jaffee, Elizabeth M, Van Dang, Chi, Agus, David B, Alexander, Brian M, Anderson, Kenneth C, Ashworth, Alan, Barker, Anna D, Bastani, Roshan, Bhatia, Sangeeta, Bluestone, Jeffrey A, Brawley, Otis, Butte, Atul J, Coit, Daniel G, Davidson, Nancy E, Davis, Mark, DePinho, Ronald A, Diasio, Robert B, Draetta, Giulio, Frazier, A Lindsay, Futreal, Andrew, Gambhir, Sam S, Ganz, Patricia A, Garraway, Levi, Gerson, Stanton, Gupta, Sumit, Heath, James, Hoffman, Ruth I, Hudis, Cliff, Hughes-Halbert, Chanita, Ibrahim, Ramy, Jadvar, Hossein, Kavanagh, Brian, Kittles, Rick, Le, Quynh-Thu, Lippman, Scott M, Mankoff, David, Mardis, Elaine R, Mayer, Deborah K, McMasters, Kelly, Meropol, Neal J, Mitchell, Beverly, Naredi, Peter, Ornish, Dean, Pawlik, Timothy M, Peppercorn, Jeffrey, Pomper, Martin G, Raghavan, Derek, Ritchie, Christine, Schwarz, Sally W, Sullivan, Richard, Wahl, Richard, Wolchok, Jedd D, Wong, Sandra L, and Yung, Alfred

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Cancer, Rare Diseases, Clinical Research, Good Health and Well Being, Biomedical Research, Forecasting, Health Planning, Health Priorities, Humans, Medical Oncology, National Cancer Institute (U.S.), Neoplasms, Precision Medicine, United States, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

Published
2017

10. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Subjects
Humans, Neoplasms, Antineoplastic Agents, Patient Advocacy, Patient Participation, Drug Costs, Prescription Fees, United States, Medical and Health Sciences
Published
2015

12. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

Author

Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans-Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., and Koopman, Miriam

Published
2018
Full Text
View/download PDF

20. Supplementary Data from 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers

Author

Zhao, Yiqing, primary, Feng, Xiujing, primary, Chen, Yicheng, primary, Selfridge, J. Eva, primary, Gorityala, Shashank, primary, Du, Zhanwen, primary, Wang, Janet M., primary, Hao, Yujun, primary, Cioffi, Gino, primary, Conlon, Ronald A., primary, Barnholtz-Sloan, Jill S., primary, Saltzman, Joel, primary, Krishnamurthi, Smitha S., primary, Vinayak, Shaveta, primary, Veigl, Martina, primary, Xu, Yan, primary, Bajor, David L., primary, Markowitz, Sanford D., primary, Meropol, Neal J., primary, Eads, Jennifer R., primary, and Wang, Zhenghe, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table S1 from Global Gene Expression Profiling of Circulating Tumor Cells

Author

Smirnov, Denis A., primary, Zweitzig, Daniel R., primary, Foulk, Bradley W., primary, Miller, M. Craig, primary, Doyle, Gerald V., primary, Pienta, Kenneth J., primary, Meropol, Neal J., primary, Weiner, Louis M., primary, Cohen, Steven J., primary, Moreno, Jose G., primary, Connelly, Mark C., primary, Terstappen, Leon W.M.M., primary, and O'Hara, S. Mark, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure S1 from Global Gene Expression Profiling of Circulating Tumor Cells

Author

Smirnov, Denis A., primary, Zweitzig, Daniel R., primary, Foulk, Bradley W., primary, Miller, M. Craig, primary, Doyle, Gerald V., primary, Pienta, Kenneth J., primary, Meropol, Neal J., primary, Weiner, Louis M., primary, Cohen, Steven J., primary, Moreno, Jose G., primary, Connelly, Mark C., primary, Terstappen, Leon W.M.M., primary, and O'Hara, S. Mark, primary

Published
2023
Full Text
View/download PDF

24. Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Author

Chakravarty, Arijit, primary, Shinde, Vaishali, primary, Tabernero, Josep, primary, Cervantes, Andres, primary, Cohen, Roger B., primary, Dees, E. Claire, primary, Burris, Howard, primary, Infante, Jeffrey R., primary, Macarulla, Teresa, primary, Elez, Elena, primary, Andreu, Jordi, primary, Rodriguez-Braun, Edith, primary, Rosello, Susana, primary, von Mehren, Margaret, primary, Meropol, Neal J., primary, Langer, Corey J., primary, ONeil, Bert, primary, Bowman, Douglas, primary, Zhang, Mengkun, primary, Danaee, Hadi, primary, Faron-Yowe, Laura, primary, Gray, Gary, primary, Liu, Hua, primary, Pappas, Jodi, primary, Silverman, Lee, primary, Simpson, Chris, primary, Stringer, Bradley, primary, Tirrell, Stephen, primary, Veiby, Ole Petter, primary, Venkatakrishnan, Karthik, primary, Galvin, Katherine, primary, Manfredi, Mark, primary, and Ecsedy, Jeffrey A., primary

Published
2023
Full Text
View/download PDF

32. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer

Author

Wong, Stuart J., Moughan, Jennifer, Meropol, Neal J., Anne, Pramila Rani, Kachnic, Lisa A., Rashid, Asif, Watson, James C., Mitchell, Edith P., Pollock, Jondavid, Lee, R. Jeffrey, Haddock, Michael, Erickson, Beth A., and Willett, Christopher G.

Published
2015
Full Text
View/download PDF

33. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

Author

Goldstein, Lori J., Zhao, Fengmin, Wang, Molin, Swaby, Ramona F., Sparano, Joseph A., Meropol, Neal J., Bhalla, Kapil N., Pellegrino, Christine M., Katherine Alpaugh, R., Falkson, Carla I., Klein, Paula, and Sledge, George W.

Published
2017
Full Text
View/download PDF

36. Application of best practice approaches for designing decision support tools: The preparatory education about clinical trials (PRE-ACT) study

Author

Fleisher, Linda, Ruggieri, Dominique G., Miller, Suzanne M., Manne, Sharon, Albrecht, Terrance, Buzaglo, Joanne, Collins, Michael A., Katz, Michael, Kinzy, Tyler G., Liu, Tasnuva, Manning, Cheri, Charap, Ellen Specker, Millard, Jennifer, Miller, Dawn M., Poole, David, Raivitch, Stephanie, Roach, Nancy, Ross, Eric A., and Meropol, Neal J.

Published
2014
Full Text
View/download PDF

39. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

Author

Meropol, Neal J., Feng, Yang, Grem, Jean L., Mulcahy, Mary F., Catalano, Paul J., Kauh, John S., Hall, Michael J., Saltzman, Joel N., George, Thomas J., Jr, Zangmeister, Jeffrey, Chiorean, Elena G., Cheema, Puneet S., OʼDwyer, Peter J., and Benson, Al B., III

Published
2018
Full Text
View/download PDF

43. Digital Health Applications in Oncology: An Opportunity to Seize

Author

Parikh, Ravi B, primary, Basen-Enquist, Karen M, additional, Bradley, Cathy, additional, Estrin, Deborah, additional, Levy, Mia, additional, Lichtenfeld, J Leonard, additional, Malin, Bradley, additional, McGraw, Deven, additional, Meropol, Neal J, additional, Oyer, Randall A, additional, Sheldon, Lisa Kennedy, additional, and Shulman, Lawrence N, additional

Published
2022
Full Text
View/download PDF

49. Radiation Therapy Oncology Group 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin With Concurrent Radiotherapy for Patients With Locally Advanced Rectal Cancer

Author

Wong, Stuart J., Winter, Kathryn, Meropol, Neal J., Anne, Pramila Rani, Kachnic, Lisa, Rashid, Asif, Watson, James C., Mitchell, Edith, Pollock, Jondavid, Lee, Robert Jeffrey, Haddock, Michael, Erickson, Beth A., and Willett, Christopher G.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results